Skandinaviska Enskilda Banken (SEB)
AIMT

Skandinaviska Enskilda Banken (SEB)’s Aimmune Therapeutics AIMT Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-54,407
Closed -$1.87M – 1185
2020
Q3 		$1.87M Buy
+54,407
New +$1.16M 0.01% 586

Skandinaviska Enskilda Banken (SEB)'s AIMT Position: Q4 2020 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 54,407 shares — an estimated $1.87M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $1.87M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 54,407 Aimmune Therapeutics shares in Q4 2020, an estimated $1.87M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Aimmune Therapeutics position peaked at $1.87M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2020, filed 11 Feb 2021.